ZNF625
Zinc finger protein 625
Also known as: ZN625_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q96I27
- Gene
- ZNF625
- Ensembl
- ENSG00000257591
- Chromosome
- 19
- Canonical length
- 306 aa
- Protein class
- Predicted intracellular proteins, Transcription factors
- Subcellular location
- Nucleoplasm,Mitochondria
OverviewNCBI Gene
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II transcription regulatory region sequence-specific DNA binding activity. Predicted to be involved in regulation of transcription by RNA polymerase II. Predicted to be active in nucleus. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
306 residues, UniProt reviewed canonical sequence.
>Q96I27|ZNF625
1 MGERLLESKK DHQHGEILTQ VPDDMLKKKT PRVKSCGEVS VGHASLNRHH RADTGHKPYE
61 YQEYGQKPYK CTYCKKAFSD LPYFRTHEWA HTGGKPYDCE ECGKSFISRS SIRRHRIMHS
121 GDGPYKCNFC GKALMCLSLY LIHKRTHTGE KPYECKQCGK AFSHSGSLRI HERTHTGEKP
181 YECSECGKAF HSSTCLHAHK ITHTGEKPYE CKQCGKAFVS FNSVRYHERT HTGEKPYECK
241 QCGKAFRSAS HLRTHGRTHT GEKPYECKQC GKAFGCASSV KIHERTHTGE KPCSSNTSKG
301 QGEKIALocalizationUniProt · AlphaFold · HPA
Whether an antibody against ZNF625 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.47
- Highest tissue expression
- 8.2 nTPM
Expression across tissuesHPA
Tissue
- retina: 8.2 nTPM
- cerebellum: 3.8 nTPM
- pituitary gland: 3 nTPM
- hypothalamus: 2.9 nTPM
- epididymis: 2.8 nTPM
- kidney: 2.7 nTPM
Single-cell type
- bergmann glia: 15 nCPM
- oligodendrocyte progenitor cells: 14 nCPM
- other brain neurons: 14 nCPM
- brain excitatory neurons: 13 nCPM
- choroid plexus epithelial cells: 12 nCPM
- ependymal cells: 11 nCPM
Immune cell
- NK-cell: 0.5 nTPM
- T-reg: 0.4 nTPM
- memory CD4 T-cell: 0.2 nTPM
- memory CD8 T-cell: 0.2 nTPM
- naive B-cell: 0.2 nTPM
- naive CD4 T-cell: 0.2 nTPM
Brain region
- cerebellum: 13 nTPM
- hypothalamus: 8.7 nTPM
- cerebral cortex: 7.4 nTPM
- medulla oblongata: 7.4 nTPM
- pons: 7.3 nTPM
- spinal cord: 7.3 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.68
- gnomAD pLI
- 0.73
- gnomAD missense Z
- 1.4
- DepMap mean gene effect
- -0.16
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
- DNA-binding transcription factor activity, RNA polymerase II-specific
- RNA polymerase II transcription regulatory region sequence-specific DNA binding
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ZNF625 as an antibody target. Whether an autoantibody or antibody against ZNF625 could matter depends on whether native ZNF625 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ZNF625 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ZNF625 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...